Assuntos
Fármacos Anti-HIV/uso terapêutico , DNA/uso terapêutico , Compostos Férricos/uso terapêutico , Infecções por HIV/tratamento farmacológico , Fármacos Anti-HIV/efeitos adversos , Fármacos Anti-HIV/farmacocinética , Contagem de Linfócito CD4 , Ensaios Clínicos como Assunto , DNA/efeitos adversos , DNA/farmacocinética , Compostos Férricos/efeitos adversos , Compostos Férricos/farmacocinética , Infecções por HIV/sangue , Infecções por HIV/virologia , Humanos , Carga ViralRESUMO
Numerous cytokines and chemokines are involved in inflammatory and immune response. Whereas some of them inhibit virus replication in vitro directly or increase the patients' T4-lymphocyte level, others effects are not so clear. Using human immunodeficiency virus (HIV) and cell cultures we have studied the antiviral effect of complexes of salmon DNA with metals and of a new factor(s) (antiviral factor, AVF) induced in cells by the complexes. The Fe3+/DNA complex possessed the highest antiviral activity. It was found that MT-2, MT-4, CEM and Jurkat cells treated with the complexes secreted AVF which inhibited the replication of nine HIV-1 isolates, was noncytotoxic and stimulated cell proliferation. AVF did not inactivate HIV. The molecular mass analysis of AVF showed that its antiviral activity is associated with its fraction of M(r) of 3 K. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of mRNA from MT-4 cells treated with the complexes showed an increase in the the expression of genes for interleukin-1 alpha (IL-1 alpha), tumour necrosis factor alpha (TNF-alpha) and TNF-beta while expression of genes for IL-1-beta, IL-2, IL-4, IL-6, IL-8. IL-10, IL-12; 35p, 40p, IL-13, GMCSF, GSF and RANTES was not detected at all. However, the anti-HIV activity of the cell culture supernatant in vitro cannot be explained by mere presence of the inflammatory substances mentioned above, because they do not possess such activity and their M(r) is higher than that of AVF. Our findings raise the possibility that AVF(s) may be involved in the mechanism of cell resistance against HIV.
Assuntos
Fármacos Anti-HIV/farmacologia , Fatores Biológicos/biossíntese , Linfócitos T CD4-Positivos/metabolismo , DNA/farmacologia , HIV-1/efeitos dos fármacos , Ferro/farmacologia , Animais , Fatores Biológicos/farmacologia , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linhagem Celular , Citocinas/metabolismo , Células Gigantes/efeitos dos fármacos , Células Gigantes/virologia , Humanos , RNA Mensageiro/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa , SalmãoAssuntos
Indutores de Interferon/farmacologia , Interferons/biossíntese , Animais , Células Cultivadas , Vírus da Encefalomiocardite , Infecções por Enterovirus/terapia , Hidrocortisona/farmacologia , Concentração de Íons de Hidrogênio , Interferons/metabolismo , Masculino , Camundongos , Especificidade de Órgãos , Temperatura , Teofilina/farmacologia , Azul Tripano/farmacologiaRESUMO
A study was carried out in Delhi on the preimmunization status of infants aged 2-6 months with regard to poliomyelitis and on seroconversion after the administration of oral poliomyelitis vaccine. It was found that 30.3% of the 204 infants included in the study excreted enteroviruses, 58% of which were found to be polioviruses. Of 197 sera examined for neutralizing antibodies against different types of poliovirus, 73% were found to be triple negative and only 4.0% triple positive. Three doses of oral poliomyelitis vaccine were administered at intervals of 1 month. It was found that 71.8% of the vaccinated infants excreted cytopathogenic agents in the 7 days following the first dose; 80.4% of these agents were found to be polioviruses. Seroconversion was studied in 71 infants, and good antibody responses to all three types of poliovirus were observed.
